NCT07264452 Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst Stimulation in Patients With Treatment-Resistant Depression
| NCT ID | NCT07264452 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ataturk University |
| Condition | Treatment Resistant Depression (TRD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-11-15 |
| Primary Completion | 2026-11-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-11-15 with a primary completion date of 2026-11-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In recent years, research on the effectiveness of transcranial magnetic stimulation (TMS) in patients with treatment-resistant depression (RTD) has been steadily increasing. The aim of this study was to examine the effectiveness of accelerated unilateral application of two different forms of theta burst stimulation (TBU), a variation of repetitive TMU (rTMS)-intermittent TBU (iTBU) and continuous TBU (cTBU)-in TDD patients. The study aimed to compare the advantages of iTBU and cTBU protocols on depression, suicidal thoughts, anxiety levels, sleep disturbances, cognitive performance, and overall functioning following a two-week intensive treatment period and a 12-week follow-up period.
Eligibility Criteria
Inclusion Criteria: 1. 18 to 65 years old 2. Patients diagnosed with Major Depressive Disorder according to DSM 5 and the severity of their illness 3. Scoring 7 points or more on the Maudsley staging method 4. Having depression unresponsive to 2 different antidepressants 5. No clinical mental retardation 6. Agree to participate in the study 7. Hamilton Depression Rating Scale-17 \[HDRS\] score of 20 or higher 8. Montgomery Asberg Depression Rating Scale \[MADRS\] score of 20 or above 9. Being right hand dominant 10. Having used the same antidepressant at the same dose for the last 4 weeks Exclusion Criteria: 1. Diagnosed with a neurological or metabolic disease that affects cognitive functions (Systemic diseases such as diabetes mellitus, cardiovascular disease, cerebrovascular disease, chronic renal failure, Parkinson's disease, multiple sclerosis, polyneuropathy, inflammatory rheumatologic disease and malignancies) 2. Having a foreign body such as a pacemaker, intracranial implant that can magnetically interact 3. Hearing and visual impairments that prevent communication 4. Unstable or acute medical conditions 5. Pregnancy or breastfeeding 6. Having a primary psychiatric disorder other than major depressive disorder 7. Being diagnosed with severe MDD with psychotic features
Contact & Investigator
Omer Faruk UYGUR, Associate professor doctor
PRINCIPAL INVESTIGATOR
Ataturk University
Frequently Asked Questions
Who can join the NCT07264452 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Treatment Resistant Depression (TRD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07264452 currently recruiting?
Yes, NCT07264452 is actively recruiting participants. Contact the research team at m.balamur5@gmail.com for enrollment information.
Where is the NCT07264452 trial being conducted?
This trial is being conducted at Erzurum, Turkey (Türkiye).
Who is sponsoring the NCT07264452 clinical trial?
NCT07264452 is sponsored by Ataturk University. The principal investigator is Omer Faruk UYGUR, Associate professor doctor at Ataturk University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.